RE: Diagnostic Advantage I looked up the writer's resume on LinkedIn. She sounds like a professional writer just starting out in her career. (She also taught English in Japan and has something to do with ballet. I know people like this. Making a living from writing or acting is a struggle and takes courage. I wish her well.)
From 2010 to the present, she worked as a senior writer and editor at a consulting company (maybe its her own company). From March through June 2012, she was a writer/editor intern at Promotive Communications, where she gathered and wrote articles for Biotechnology Focus and Laboratory Focus magazines. I assume Promotive is the publisher for these trade magazines.
So it sounds like Diagnocure may have paid to have this article written and published. But what was the purpose? To make the stock price go up? The stock price will go up when their revenue grows. Their motive is puzzling.
As for accuracy in the article, it appears the author finished the article in June, after which her assignment with Promotive Communications ended. It then took them 4 months to publish the article. There is some lead time in publishing magazines, so this makes sense. She finished before Diagnocure announced in early September that Signal Genetics had stopped paying and had closed the GCC Lab in July. She had no way of knowing. If she had contacted Signal to confirm they were funding the GCC clinical trial, she would have done it in May, which is just after the President of Signal left the business. Its not clear what Signal might have said.